The JMJD4 Knockout NCI-H1975 Polyclonal Cells consist of a heterogeneous population of NCI-H1975 human lung adenocarcinoma cells edited using CRISPR/Cas9 technology to disrupt the JMJD4 gene. This polyclonal knockout product provides a loss-of-function model for studying the biological roles of JMJD4, a lysyl hydroxylase involved in ribosomal protein modification. The polyclonal format captures a range of editing events, making it suitable for pooled functional assessments without the limitations of single-cell clonal selection.
The parental NCI-H1975 cell line originates from a non-smoking female patient with non-small cell lung cancer (NSCLC) and carries both the EGFR L858R activating mutation and the T790M gatekeeper mutation. These mutations render the line dependent on mutant EGFR signaling and are associated with acquired resistance to first- and second-generation EGFR inhibitors. Consequently, NCI-H1975 is a well-established model for investigating oncogenic signaling, drug resistance mechanisms, and therapeutic vulnerabilities in EGFR-mutant lung adenocarcinomas.
JMJD4 functions as a Fe2+- and 2-oxoglutarate-dependent lysyl hydroxylase that specifically catalyzes hydroxylation of ribosomal protein L8 (RPL8) at key lysine residues. This post-translational modification is critical for proper ribosome assembly and translational fidelity, linking JMJD4 activity to the broader pathway of ribosome biogenesis. Transcriptional control of JMJD4 is influenced by upstream factors including MYC and hypoxia-inducible factors, integrating its expression with cellular growth and stress signals. In turn, JMJD4-mediated RPL8 hydroxylation modulates the ribosomal translation machinery, impacting elongation and the synthesis of specific protein subsets. Thus, JMJD4 serves as a regulatory node connecting oncogenic and environmental cues to translational output through its interaction with RPL8 and essential cofactors.
In the context of EGFR-driven lung adenocarcinoma, dysregulated protein synthesis is increasingly recognized as a contributor to malignant phenotypes and therapeutic resistance. JMJD4-dependent ribosome modification may facilitate the selective translation of oncogenic factors or stress-response proteins that support tumor survival under EGFR inhibitor pressure. Disruption of JMJD4 in NCI-H1975 cells is therefore expected to impair ribosomal function, potentially attenuating proliferation, altering stress responses, and modulating sensitivity to targeted agents. This polyclonal knockout model provides a clinically relevant platform to dissect how translational control mechanisms influence NSCLC pathophysiology and treatment outcomes.
Researchers can employ this JMJD4 knockout polyclonal product in a variety of experimental contexts, including ribosome profiling and polysome fractionation to assess translational changes, proliferation and migration assays to evaluate tumor cell behavior, and drug sensitivity screens with EGFR inhibitors to explore resistance mechanisms. The polyclonal nature minimizes clonal artifacts and allows identification of robust, population-level phenotypes. These applications support studies on the role of protein hydroxylation in lung cancer, the contribution of translational control to EGFR-mutant NSCLC progression, and the validation of JMJD4 as a potential therapeutic target. For additional information or technical support, please contact Ascent Research.
